Endo International Plc (ENDPQ) Gross Profit Margin starting from the fourth quarter 2023 to fourth quarter 2022, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Endo International Plc  (ENDPQ)


Endo International Plc's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ENDPQ Gross Profit Margin (Dec 31 2023)
Q4 		(Sep 30 2023)
Q3 		(Jun 30 2023)
Q2 		(Mar 31 2023)
Q1 		(Dec 31 2022)
Q4
Y / Y Revenue Change -10.45 %
Seq. Revenue Change 10.2 %
Revenue In Millions $497.73
Gross Profit Margin 49.87 %
Gross Profit Margin Total Ranking # 1803
Gross Profit In Millions $248.20
Y / Y Gross Profit Change -5.1 %
Seq. Gross Profit Change 12.11 %


Commenting fourth quarter 2023 Gross Profit Margin
Endo International Plc Gross Profit grew by 12.11 % in Q4 sequentially to 248 millions, while Revenue increased by 10.2 %, this led to improvement in the company's Gross Profit Margin to 49.87 %, above the Endo International Plc average Gross Profit Margin.


Observing fourth quarter 2023 results within Major Pharmaceutical Preparations industry 120 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 1803, from total ranking in the previous quarter at 1862.
Learn about Gross Margin
ENDPQ's Gross Profit Margin fourth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 322
Overall # 1783

Gross Profit Margin Statistics
High Average Low
62.95 % 46.37 % 24.55 %
(Sep 30 2021)   (Dec 31 2015)


ENDPQ Gross Income Trends • More of ENDPQ's Profitabilty Ratios • ENDPQ Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
ENDPQ's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
ENDPQ's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for ENDPQ's Competitors
Gross Profit Margin Profit Margin for Endo International Plc's Suppliers
Gross Profit Margin Profit Margin for ENDPQ's Customers

You may also want to know
ENDPQ's Annual Growth Rates ENDPQ's Profitability Ratios ENDPQ's Asset Turnover Ratio ENDPQ's Dividend Growth
ENDPQ's Roe ENDPQ's Valuation Ratios ENDPQ's Financial Strength Ratios ENDPQ's Gross Profit Growth
ENDPQ's Roa ENDPQ's Inventory Turnover Ratio ENDPQ's Growth Rates ENDPQ's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Gross Profit MarginDec 31 2023 MRQ Gross ProfitDec 31 2023 MRQ Revenue
Carisma Therapeutics Inc   99.74 %$ 4.289  Millions$ 4.300  Millions
Blueprint Medicines Corporation  99.67 %$ 77.516  Millions$ 77.776  Millions
Ionis Pharmaceuticals Inc   99.06 %$ 321.443  Millions$ 324.505  Millions
Corcept Therapeutics Inc  98.61 %$ 133.529  Millions$ 135.405  Millions
Macrogenics Inc   98.48 %$ 10.557  Millions$ 10.720  Millions
Sage Therapeutics Inc   98.28 %$ 76.631  Millions$ 77.971  Millions
Serina Therapeutics Inc   98.21 %$ 0.055  Millions$ 0.056  Millions
Emmaus Life Sciences Inc   97.16 %$ 6.534  Millions$ 6.725  Millions
Lexaria Bioscience Corp   96.81 %$ 0.146  Millions$ 0.151  Millions
Reshape Lifesciences Inc  96.34 %$ 1.842  Millions$ 1.912  Millions
Deciphera Pharmaceuticals Inc   96.30 %$ 46.509  Millions$ 48.294  Millions
Aclaris Therapeutics Inc   95.87 %$ 16.845  Millions$ 17.570  Millions
Karyopharm Therapeutics Inc   95.60 %$ 32.261  Millions$ 33.747  Millions
Gyre Therapeutics Inc   95.40 %$ 25.898  Millions$ 27.148  Millions
Calliditas Therapeutics Ab  95.36 %$ 123.241  Millions$ 129.241  Millions
Palatin Technologies Inc   95.20 %$ 1.936  Millions$ 2.034  Millions
Lexicon Pharmaceuticals Inc   93.30 %$ 0.655  Millions$ 0.702  Millions
Vanda Pharmaceuticals Inc   92.36 %$ 41.811  Millions$ 45.271  Millions
Acadia Pharmaceuticals Inc   92.26 %$ 213.151  Millions$ 231.041  Millions
Agios Pharmaceuticals Inc   91.75 %$ 6.517  Millions$ 7.103  Millions
Silo Pharma Inc  91.52 %$ 0.017  Millions$ 0.018  Millions
Amylyx Pharmaceuticals Inc   91.37 %$ 99.089  Millions$ 108.449  Millions
Regeneron Pharmaceuticals Inc   91.07 %$ 3,127.500  Millions$ 3,434.300  Millions
Ocular Therapeutix Inc   90.64 %$ 13.416  Millions$ 14.802  Millions
Ultragenyx Pharmaceutical Inc   90.54 %$ 115.341  Millions$ 127.392  Millions
Urogen Pharma Ltd   90.28 %$ 21.244  Millions$ 23.530  Millions
Amicus Therapeutics inc   90.16 %$ 103.758  Millions$ 115.082  Millions
Verrica Pharmaceuticals Inc   89.94 %$ 1.788  Millions$ 1.988  Millions
Pharming Group N v   89.80 %$ 220.104  Millions$ 245.104  Millions
Axsome Therapeutics Inc   89.69 %$ 64.152  Millions$ 71.530  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.